Paid Plans
Want to analyze multiple companies at once? Paid plans let you compare up to 5 stocks side by side.
Sign Up
E
ENP
vs
S
S&P/ASX 300
Over the past 12 months, ENP has underperformed S&P/ASX 300, delivering a return of -3% compared to S&P/ASX 300's 1% drop.
Stocks Performance
ENP vs S&P/ASX 300
Performance Gap
ENP vs S&P/ASX 300
Performance By Year
ENP vs S&P/ASX 300
Compare the stock's returns with its benchmark index and competitors. Gain insights into its relative performance over time.
Entropy Neurodynamics Ltd
Glance View
Tryptamine Therapeutics Ltd is a drug-development company focused on medicines built around tryptamine compounds, the chemical family that includes well-known psychedelic molecules. Its work is aimed at turning those compounds into controlled pharmaceutical treatments, especially for mental health and other medical uses where standard drugs may not be enough. The company does not sell a finished drug at scale today. Instead, it earns money like many early-stage biotech firms: by raising capital from investors, and potentially through research partnerships, licensing deals, or grant funding as its programs move forward. Its main “customers” are not patients yet, but rather future pharmaceutical partners, regulators, and eventually doctors and hospitals if a therapy is approved. What makes its business model different is that it sits very early in the drug pipeline and depends on turning a niche class of molecules into regulated medicines. That means its value comes from scientific data, intellectual property, and clinical progress rather than from manufacturing or mass sales. If its programs succeed, it could become a source of novel treatments that larger drug companies may license, develop, or commercialize.